Oncolytics Biotech (ONCY) Enterprise Value (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Enterprise Value of -$5.2 million for Q4 2025, up 57.06% year-over-year from -$3.3 million in Q4 2024, and up 42.04% quarter-over-quarter from -$9.0 million in Q3 2025.
Oncolytics Biotech (ONCY) Enterprise Value (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Enterprise Value for 17 consecutive years, with -$5.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 57.06% year-over-year to -$5.2 million; the TTM figure through Dec 2025 stood at -$5.2 million (up 57.06% YoY), while the FY2025 annual figure was -$5.2 million, up 57.91% from the prior year.
- Enterprise Value grew to -$5.2 million in Q4 2025 per ONCY's latest filing, from -$9.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.2 million in Q4 2025 and bottomed at -$41.3 million in Q2 2021.
- Historically, Enterprise Value has averaged -$21.3 million across 5 years, with a median of -$20.1 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 73.75% — and 2023, when it sank 198.38%.
- Oncolytics Biotech's Enterprise Value stood at -$32.7 million in 2021, then surged by 73.75% to -$8.6 million in 2022, then plunged by 198.38% to -$25.6 million in 2023, then surged by 52.76% to -$12.1 million in 2024, then soared by 57.06% to -$5.2 million in 2025.
- Business Quant data shows ONCY's Enterprise Value at -$5.2 million in Q4 2025, -$9.0 million in Q3 2025, and -$10.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | -4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.12 Mn |
| Dec 31, 2025 | -5.20 Mn |
| Sep 30, 2025 | -8.98 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -10.66 Mn |
| Dec 31, 2024 | -12.11 Mn |
| Sep 30, 2024 | -14.37 Mn |
| Jun 30, 2024 | -18.17 Mn |
| Mar 31, 2024 | -21.97 Mn |
| Dec 31, 2023 | -25.64 Mn |
| Sep 30, 2023 | -29.82 Mn |
| Jun 30, 2023 | -13.04 Mn |
| Mar 31, 2023 | -11.74 Mn |
| Dec 31, 2022 | -8.59 Mn |
| Sep 30, 2022 | -24.81 Mn |
| Jun 30, 2022 | -26.42 Mn |
| Mar 31, 2022 | -31.17 Mn |
| Dec 31, 2021 | -32.73 Mn |
| Sep 30, 2021 | -38.20 Mn |
| Jun 30, 2021 | -41.33 Mn |